Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
October 06, 2018 at 18:57 PM EDT
Shanghai Fosun Pharma announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary The company was established to develop mAb biosimilar drugs, bio-betters and novel mAbs.